BioSight
Companies
Corvus Pharmaceuticals, Inc. logo

CRVS

NASDAQSOUTH SAN FRANCISCO, CA
Corvus Pharmaceuticals, Inc.

Corvus Pharmaceuticals develops small-molecule drug candidates targeting cancer and immune-related diseases. The company has three lead programs in clinical development: soquelitinib (a kinase inhibitor), ciforadenant (an adenosine pathway modulator), and mupadolimab (an immune checkpoint candidate). Corvus is in the clinical trial stage with these candidates and is pursuing strategic partnerships to advance its pipeline toward potential commercialization.

Price history not yet available for CRVS.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar